Age ≤ 60 years: Patients with allo-HSCT indication at CR1: Patients in the good prognosis group according to WHO stratification criteria generally do not require allo-HSCT at CR1, and the decision to transplant can be based on the change in microscopic residual disease (MRD) after intensive therapy, such as a decrease in AML/ETO of less than 3log after 2 courses of consolidation and intensive therapy or a change from negative to positive after intensive therapy. to positive after intensive therapy. Prognosis intermediate risk group according to WHO stratification criteria; III. In the prognosis {risk group according to WHO stratification criteria. Achieved CR1 after more than 2 courses. AML transformed from myelodysplastic syndrome (MDS) or treatment-related AML. Stage ≥CR2 with allo-HSCT indication: patients with AML with first hematologic relapse who have achieved CR2 with induction therapy or salvage therapy, aim for early allo-HSCT; patients with any type of AML in stage ≥CR3 with indications for transplantation. AML without CR: Refractory and relapsed AML of all types that cannot achieve CR and can undergo salvage allo-HSCT are recommended to be attempted in an experienced unit. Age > 60 years: If the patient’s disease meets the above criteria and the physical condition is compatible with allo-HSCT, allo-HSCT is recommended to be attempted in an experienced unit.